GSK to Acquire RAPT Therapeutics for $2.2 Billion, Adding Food Allergy Therapy

GSK announced a $2.2 billion deal to acquire US-based biopharma company RAPT Therapeutics, gaining global rights to its experimental food allergy therapy ozureprubart, excluding certain Asian regions. The therapy offers less frequent dosing compared to existing treatments. The acquisition, advised by Evercore and J.P. Morgan, is GSK's first major move under CEO Luke Miels, aiming to strengthen its pipeline amid patent expirations. RAPT's stock surged over 63% in pre-market trading following the announcement.